INVENTIVA ADS/1 O.N.
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat … Read more
INVENTIVA ADS/1 O.N. (6IVA) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, INVENTIVA ADS/1 O.N. (6IVA) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
INVENTIVA ADS/1 O.N. - Net Assets Trend (None–None)
This chart illustrates how INVENTIVA ADS/1 O.N.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for INVENTIVA ADS/1 O.N. (None–None)
The table below shows the annual net assets of INVENTIVA ADS/1 O.N. from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to INVENTIVA ADS/1 O.N.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
INVENTIVA ADS/1 O.N. Competitors by Market Cap
The table below lists competitors of INVENTIVA ADS/1 O.N. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vijaya Diagnostic Centre Limited
NSE:VIJAYA
|
$530.99 Million |
|
COHANCE
NSE:COHANCE
|
$531.19 Million |
|
Tianjin Port Development Holdings Limited
PINK:TJIPY
|
$531.23 Million |
|
Compania Nationala de Transport al Energiei Electrice Transelectrica SA
RO:TEL
|
$531.25 Million |
|
Delta Galil Industries Ltd
OTCGREY:DELTF
|
$530.69 Million |
|
Wuxi Online Offline Communication Information Technology Co. Ltd.
SHE:300959
|
$530.67 Million |
|
Sansteel MinGuang Co Ltd Fujian
SHE:002110
|
$530.66 Million |
|
Xinjiang Beixin Road&Bridge Group Co Ltd
SHE:002307
|
$530.59 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in INVENTIVA ADS/1 O.N.'s equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares INVENTIVA ADS/1 O.N.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently INVENTIVA ADS/1 O.N. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares INVENTIVA ADS/1 O.N.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,291,084,078
- Average return on equity (ROE) among peers: -24.49%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| INVENTIVA ADS/1 O.N. (6IVA) | €- | N/A | N/A | $530.73 Million |
| 09R (09R) | $-3.01 Million | 0.00% | 0.00x | $11.12 Million |
| IDORSIA AG (19T) | $-968.72 Million | 0.00% | 0.00x | $532.51 Million |
| 1S90 (1S90) | $-44.86 Million | 0.00% | 0.00x | $51.72 Million |
| Strategic Partners A/S (1TB0) | $14.24 Million | -182.90% | 0.36x | $1.31 Million |
| 25K0 (25K0) | $-16.66 Million | 0.00% | 0.00x | $102.39 Million |
| 2BO (2BO) | $-37.78 Million | 0.00% | 0.00x | $6.23 Million |
| Intervacc AB (publ) (2E9) | $237.93 Million | -43.23% | 0.09x | $3.46 Million |
| 2F5 (2F5) | $-4.57 Million | 0.00% | 0.00x | $2.14 Million |
| 2H0 (2H0) | $14.92 Million | -17.30% | 0.56x | $9.25 Million |
| GNI Group Ltd (3G6) | $13.72 Billion | -1.46% | 0.26x | $772.60 Million |